N/A
Manufactured by Padagis US LLC
4,882 FDA adverse event reports analyzed
Last updated: 2026-04-15
TROSPIUM CHLORIDE is a medication tracked in the FDA Adverse Event Reporting System (FAERS), manufactured by Padagis US LLC. The most commonly reported adverse reactions for TROSPIUM CHLORIDE include FALL, FATIGUE, URINARY TRACT INFECTION, DRUG INEFFECTIVE, DYSPNOEA. This page provides a comprehensive breakdown of reported side effects, safety signals, patient demographics, and AI-powered safety analysis for TROSPIUM CHLORIDE.
Out of 2,140 classified reports for TROSPIUM CHLORIDE:
The FDA classifies an adverse event as “serious” if it results in death, hospitalization, disability, congenital anomaly, or requires intervention to prevent permanent damage.
Demographics reflect voluntary FDA adverse event reporting patterns and may not represent the full patient population.
This profile reflects 4,882 FDA FAERS reports that mention TROSPIUM CHLORIDE. Reporting is voluntary and does not prove that the drug caused any listed event.
Frequently reported terms in FAERS include FALL, FATIGUE, URINARY TRACT INFECTION, DRUG INEFFECTIVE, DYSPNOEA, ASTHENIA. Rankings reflect reporting volume in this dataset, not confirmed side effect rates in the general population.
Labeling and FAERS entries often list Padagis US LLC in connection with TROSPIUM CHLORIDE. Always verify the specific product and NDC with your pharmacist.